Effect of probucol on the activity of postheparin plasma lipoprotein lipase and hepatic lipase.
The effect of discontinuation of long term (34-56 months) probucol treatment on serum lipids, lipoproteins and on the activity of postheparin plasma lipoprotein and hepatic lipase ahs been studied in 10 healthy males participating in a primary prevention programme of coronary heart disease. A significant increase was observed in the activity of postheparin plasma lipoprotein lipase, in the total serum cholesterol concentration and in the serum concentrations of high density lipoprotein (HDL) cholesterol, HDL phospholipids and apoprotein AI after withdrawal of the drug No changes were seen in the serum triglyceride levels or in the activity of postheparin plasma hepatic lipase. The activity of postheparin plasma hepatic lipase tended to correlate with the serum concentration of HDL. No correlations were present between the individual changes in the serum levels of HDL and in the activity of postheparin plasma triglyceride lipases.
D016632:Apolipoprotein A-I; D001053:Apolipoproteins / Q000097:blood; D002784:Cholesterol / Q000097:blood; D008076:Cholesterol, HDL; D003327:Coronary Disease / Q000517:prevention & control; D006493:Heparin / Q000494:pharmacology; D006801:Humans; D008049:Lipase / Q000378:metabolism*; D008071:Lipoprotein Lipase / Q000097:blood*; D008075:Lipoproteins, HDL / Q000097:blood; D008099:Liver / Q000201:enzymology*; D008297:Male; D008875:Middle Aged; D010636:Phenols; D010743:Phospholipids / Q000097:blood; D011341:Probucol
D016632:Apolipoprotein A-I; D001053:Apolipoproteins; D008076:Cholesterol, HDL; D008075:Lipoproteins, HDL; D010636:Phenols; D010743:Phospholipids; D006493:Heparin; D002784:Cholesterol; D008049:Lipase; D008071:Lipoprotein Lipase; D011341:Probucol